ABBV vs ONC: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ABBV is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABBV and ONC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABBV and ONC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. It focuses on discovering and commercializing medicines for immunology, oncology, neuroscience, and aesthetics. Its immunology franchise anchors the business: historically through Humira (adalimumab), and increasingly through Skyrizi (risankizumab) and Rinvoq (upadacitinib), which treat conditions such as plaque psoriasis, Crohn's disease, rheumatoid arthritis, and ulcerative colitis. Oncology contributes through Imbruvica (developed in collaboration with Johnson and Johnson) and Venclexta (in collaboration with Roche), while the 2020 acquisition of Allergan added Botox Therapeutic, Vraylar, and the aesthetics portfolio including Botox Cosmetic and Juvederm. Revenue is generated by selling branded pharmaceuticals at negotiated prices to wholesale distributors, specialty pharmacies, and health systems across more than 175 countries.

Full ABBV guide

BeOne Medicines is a global oncology company built around one large drug. BRUKINSA (zanubrutinib), a BTK inhibitor used in chronic lymphocytic leukemia and other B-cell cancers, produced ~$1.2 billion of the ~$1.68 billion in product revenue it booked in the second quarter of 2026. Around it sit TEVIMBRA (tislelizumab), a PD-1 antibody; BEQALZI (sonrotoclax), a BCL2 inhibitor that won U.S. accelerated approval in relapsed or refractory mantle cell lymphoma; ZIIHERA (zanidatamab) in HER2-positive gastroesophageal cancer; and in-licensed Amgen products sold in China. The company was BeiGene until recently. Its Nasdaq listing began trading under symbol ONC instead of BGNE on January 2, 2025, and effective May 27, 2025 the company moved its jurisdiction of incorporation from the Cayman Islands to Switzerland and took the BeOne Medicines name. What a U.S. holder actually owns is an American Depositary Share representing 13 ordinary shares, the same shares listed in Hong Kong (06160) and, as RMB shares, on Shanghai's STAR Market (688235).

Full ONC guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ABBV drivers: Skyrizi and Rinvoq replacing Humira faster than expected; Neuroscience becoming a meaningful second growth engine.
• ONC drivers: BRUKINSA taking share in B-cell cancers; Costs growing slower than revenue.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. For ONC, concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABBV if you believe its drivers more; ONC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABBV and ONC guides.

ABBV. The large gap between the trailing GAAP P/E (elevated, reflecting non-cash acquired IPR and D charges on recent deals) and the forward P/E of roughly 15.7x illustrates why analysts and management prefer adjusted metrics: large upfront licensing and milestone payments depress reported earnings without reducing cash generation. On a free cash flow basis, AbbVie trades at a more modest multiple, and the PEG ratio near 0.91 suggests the consensus earnings growth rate is tracking faster than the headline valuation implies. The 2026 revenue guidance of roughly $67 billion and adjusted EPS of $14.37 to $14.57 would, if achieved, represent meaningful upward re-rating from 2025 reported figures.

ONC. Figures come from the Form 10-Q for the quarter ended June 30, 2026 and the accompanying Q2 2026 earnings release filed with the SEC on August 5, 2026. The company reports in U.S. dollars, so no conversion is involved despite the Swiss domicile and the Hong Kong and Shanghai listings. Note that per-ADS figures are 13 times the per-ordinary-share figures, which is why a screener showing EPS of $0.16 and one showing $2.12 can both be right.

Headline figures (approximate, 2026-06-27): ABBV shows revenue (fy 2025, reported) ~$61.2 billion, adjusted diluted eps (fy 2025) $10.00, gaap diluted eps (fy 2025) $2.36, forward p/e (consensus fy 2026 estimate) ~15.7x; ONC shows revenue (ttm) ~$6.13B, q2 2026 revenue ~$1.71B, up ~30% year over year, gaap net income (ttm) ~$656M (FY2025 was ~$287M, FY2024 a ~$645M loss), q2 2026 diluted eps per ads ~$2.05 GAAP, ~$3.84 adjusted.

ABBV and ONC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABBV and ONC exposure against your real portfolio. It is not an investment adviser.